Analysts Offer Insights on Healthcare Companies: Telesis Bio (TBIO) and Springworks Therapeutics (SWTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Telesis Bio (TBIO – Research Report) and Springworks Therapeutics (SWTX – Research Report) with bullish sentiments.

Telesis Bio (TBIO)

TD Cowen analyst Steven Mah maintained a Buy rating on Telesis Bio today. The company’s shares closed last Tuesday at $0.55, close to its 52-week low of $0.30.

According to TipRanks.com, Mah has 0 stars on 0-5 stars ranking scale with an average return of -8.7% and a 32.3% success rate. Mah covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Ginkgo Bioworks Holdings, and Rapid Micro Biosystems.

The the analyst consensus on Telesis Bio is currently a Moderate Buy rating.

See today’s best-performing stocks on TipRanks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TBIO:

• Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
• Telesis Bio sees Q4 revenue $7M vs. $9.5M last year